What is the share price of Vysali Pharmaceuticals Ltd (524290)?

Company share prices are keep on changing according to the market conditions. The current trading price of Vysali Pharmaceuticals Ltd (524290) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Vysali Pharmaceuticals?

The latest standalone P/E ratio of Vysali Pharmaceuticals as of 01-Jan-1970 is 0.00.

What is the P/B ratio of Vysali Pharmaceuticals Ltd (524290)?

The latest standalone P/B ratio of Vysali Pharmaceuticals Ltd (524290) as of 01-Jan-1970 is -0.26.

What is the 52-week high and low of Vysali Pharmaceuticals Ltd (524290)?

The 52-week high of Vysali Pharmaceuticals Ltd (524290) is Rs. 0.00 and the 52-week low is Rs. 0.00.

Vysali Pharmaceuticals Ltd (524290) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Vysali Pharmaceuticals Ltd (524290)
Brand: Vysali Pharmaceuticals

Vysali Pharmaceuticals Ltd (524290)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524290 NSE: Pharmaceuticals & Drugs | Small Cap | Vysali Pharma Share Price

Vysali Pharmaceuticals Ltd (524290)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524290 NSE: Pharmaceuticals & Drugs | Small Cap | Vysali Pharma Share Price

Key Metrics

Valuation Multiples

Market Cap

₹2 Cr.

Current Price

₹0

52-Week Low / High

₹0 / 0

TTM EPS

₹-5.8

TTM Sales

₹1.2 Cr.

Book Value per Share

₹-16.2

P/E Ratio

0.00

Industry PE

46.6

Price to Book (P/B)

-0.26

Price to Sales (P/S)

1.99

EV/EBITDA

-8.78

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

0.00%

Return on Capital Employed (ROCE)

-18.61%

Return on Assets (ROA)

-18.17%

Operating Profit Margin

-159%

Net Profit Margin

-270.05%

Gross Profit Margin

-214.9%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-75.42%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

Pledged shares (%) of Promoter's holding (%)

Reserves

₹-14 Cr.

Equity

₹5.4 Cr.

Face Value

₹10

All Time Low / High

₹0.70 / 34.00

Vysali Pharmaceuticals stock performance

Key Ratios

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Jun'99	Jun'00	Sep'01	Mar'03	Mar'04	Mar'05	Mar'06	Jun'07	Mar'08	Mar'09	TTM
ROCE % ⓘ	12.5%	-9.3%	12%	-1.4%	-14.2%	-31.7%	-48.9%	-2%	-48.5%	-18.6%	-
Growth Parameters ⓘ
Sales ⓘ	15.8	12.9	11.8	12.7	8	7	5.1	8.1	4.8	1.2	1
Sales YoY Gr.	-	-18.2%	-9.2%	7.9%	-37.2%	-12.6%	-26.6%	58.7%	-41.3%	-75.4%	-
Adj EPS ⓘ	-1	-9.1	1.2	-3.1	-7.9	-9	-9.3	-0.9	-26.3	-5.9	-5.8
YoY Gr.	-	NA	NA	-352%	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	11.8	3.7	4.2	0.4	-7.2	-16.2	-25.5	17.2	2.4	-4.1	-16.2
Adj Net Profit ⓘ	-0.6	-4.9	0.7	-1.7	-4.3	-4.9	-5	-0.5	-14.3	-3.2	-3
Cash Flow from Ops. ⓘ	-2.3	-2.8	0.4	-2	-0.1	-0.4	-0.2	9.8	-1.9	0	-
Debt/CF from Ops. ⓘ	-5.7	-6.5	34.5	-7	-223.3	-57.7	-99	0.8	-8.9	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-25.1%	-31.9%	-38.8%	-75.4%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	-188.8%	NA	NA	-270.9%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

	Jun'99	Jun'00	Sep'01	Mar'03	Mar'04	Mar'05	Mar'06	Jun'07	Mar'08	Mar'09	TTM
Return on Equity % ⓘ	-7.7	-110.6	33.8	-154.3	244.5	77.2	44.5	54.7	-169.5	515.8	57.3
Op. Profit Mgn % ⓘ	16.5	-15	7.8	-4.5	-42.2	-64.1	-101.9	-3.9	-232.9	-159	-54.8
Net Profit Mgn % ⓘ	-3.5	-38.2	5.7	-13.3	-53.9	-70.5	-98.4	-5.8	-300.6	-272.2	-269.6
Debt to Equity ⓘ	2	8.9	6.1	64	-5.3	-2.4	-1.5	0.9	12.9	-6.2	-
Working Cap Days ⓘ	428	545	463	374	813	750	721	291	529	390	0
Cash Conv. Cycle ⓘ	343	450	371	310	695	634	591	214	389	-55	0

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Jun'99	Jun'00	Sep'01	Mar'03	Mar'04	Mar'05	Mar'06	Jun'07	Mar'08	Mar'09
Sales	15.82	12.94	14.68	19.01	7.96	6.96	5.11	10.14	3.57	1.17
Operating Expenses ⓘ +	13.20	14.88	13.54	19.86	11.32	11.42	10.32	10.54	11.87	3.03
Manufacturing Costs	4.13	3.07	3.45	4.56	2.26	1.64	2.01	3.25	1.32	0.30
Material Costs	3.97	7.17	5.84	8.58	4.24	6.90	2.95	4.01	4.71	0.52
Employee Cost	2.32	2.06	2.22	2.76	2	1.70	1.21	1.75	1.12	0.54
Other Costs ⓘ	2.78	2.57	2.04	3.96	2.83	1.18	4.15	1.53	4.72	1.66
Operating Profit ⓘ	2.61	-1.94	1.14	-0.85	-3.36	-4.46	-5.21	-0.39	-8.31	-1.86
Operating Profit Margin (%)	16.5%	-15.0%	7.8%	-4.5%	-42.2%	-64.1%	-101.0%	-3.9%	-232.0%	-159.0%
Other Income ⓘ +	0.07	0.11	2.03	1.08	0.97	0.21	0.76	0.54	0.12	0.05
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	2.74	3.10	1.60	2.22	1.55	0.31	0.23	0.27	2.13	0.79
Depreciation ⓘ	0.49	0	0.74	0.52	0.35	0.35	0.35	0.44	0.38	0.50
Profit Before Tax ⓘ	-0.54	-4.93	0.83	-2.51	-4.29	-4.91	-5.02	-0.57	-10.70	-3.09
Tax ⓘ	0	0	0	0	0	0	0.01	0.01	0.02	0.07
Profit After Tax	-0.54	-4.93	0.83	-2.51	-4.29	-4.91	-5.03	-0.57	-10.72	-3.16
PAT Margin (%)	-3.4%	-38.1%	5.7%	-13.2%	-53.9%	-70.5%	-98.4%	-5.7%	-300.0%	-270.0%
Adjusted EPS (₹)	-1.0	-9.1	1.5	-4.6	-7.9	-9.0	-9.3	-1.1	-19.8	-5.8
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Vysali Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Jun'99	Jun'00	Sep'01	Mar'03	Mar'04	Mar'05	Mar'06	Jun'07	Mar'08	Mar'09
Equity and Liabilities
Shareholders Fund +	6.89	2.04	2.88	0.39	-3.90	-8.81	-13.84	11.69	0.96	-2.20
Share Capital ⓘ	5.43	5.43	5.43	5.43	5.43	5.43	5.43	5.43	5.43	5.43
Reserves ⓘ	1.47	-3.38	-2.55	-5.04	-9.33	-14.23	-19.26	6.26	-4.46	-7.62
Debt +	12.97	18	17.62	21.43	20.70	21.02	21.22	10.25	12.43	13.53
Long Term Debt	12.97	18	17.62	21.43	20.70	21.02	21.22	10.25	12.43	13.53
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	2.98	3	3.14	2.81	2.12	2.06	1.64	1.98	1.96	1.85
Others Liabilities ⓘ	5.55	1.12	1.63	1.95	2.26	3.03	3.01	3.16	3.03	3.17
Total Liabilities ⓘ	28.39	24.16	25.27	26.58	21.18	17.31	12.03	27.08	18.39	16.35
Fixed Assets
Net Fixed Assets ⓘ +	3.91	4.02	5.12	4.73	4.37	4.03	3.68	16.58	16.23	15.75
Gross Block	7.12	7.19	7.45	7.57	7.56	7.54	7.55	20.88	20.46	20.47
Accumulated Depreciation	3.21	3.17	2.32	2.84	3.18	3.52	3.87	4.30	4.23	4.73
CWIP ⓘ	0	0.06	0	0.02	0.03	0.03	0.03	0.03	0	0.03
Investments ⓘ	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Inventories	16.04	12.85	13.92	14.61	13.99	9.86	7.13	6.91	0.69	0.30
Trade Receivables	5.74	6.39	5.17	5.71	2.43	3.02	0.85	1.90	1.09	0.01
Cash Equivalents	1.76	0.45	0.40	0.94	0.12	0.07	0.05	1.37	0.08	0.02
Others Assets ⓘ	0.94	0.38	0.64	0.56	0.23	0.28	0.27	0.27	0.27	0.21
Total Assets ⓘ	28.39	24.16	25.27	26.58	21.18	17.31	12.03	27.08	18.39	16.35

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Jun'99	Jun'00	Sep'01	Mar'03	Mar'04	Mar'05	Mar'06	Jun'07	Mar'08
Cash Flow From Operating Activity ⓘ +	-2.26	-2.78	0.51	-3.06	-0.09	-0.36	-0.21	12.29	-1.40
PBT ⓘ	-0.54	-4.99	-0.03	-2.51	-4.29	-4.91	-5.03	12.20	-10.73
Adjustment ⓘ	3.21	3.16	1.47	2.53	1.83	0.62	0.58	0.71	2.49
Changes in Working Capital ⓘ	-2.78	1.67	0.53	-1.1	3.82	4.16	4.39	-0.47	6.84
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-0.27	-0.11	-0.18	-0.12	-0.01	0	-0	-0.01	0.01
Capex	-0.32	-0.16	-0.20	-0.15	-0.01	0	-0	-0.01	-0
Net Investments	-0.02	0	0	0	0	0	0	0	0
Others ⓘ	0.07	0.04	0.02	0.03	0	0	0	0	0.02
Cash Flow From Financing Activity ⓘ +	3.70	1.59	-0.39	3.72	-0.72	0.32	0.20	-10.97	0.09
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0.12
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0
Others ⓘ	3.70	1.59	-0.39	3.72	-0.72	0.32	0.20	-10.97	-0.02
Net Cash Flow ⓘ	1.17	-1.31	-0.05	0.54	-0.82	-0.04	-0.02	1.32	-1.29

Financial Ratio

PARTICULARS	Jun'99	Jun'00	Sep'01	Mar'03	Mar'04	Mar'05	Mar'06	Jun'07	Mar'08	Mar'09
Ratios
ROE (%)	-8.51	-117.33	33.93	-156.4	N/A	N/A	N/A	0	-169.47	N/A
ROCE (%)	12.54	-9.27	12.02	-1.36	N/A	N/A	N/A	-2.01	-48.5	N/A
Asset Turnover Ratio	0.66	0.53	0.63	0.76	0.35	0.38	0.37	0.56	0.17	0.07
PAT to CFO Conversion(x)	N/A	N/A	0.61	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	107.30	158.20	136.10	100.30	176.80	137.30	130.50	46.20	142.30	167
Inventory Days	313.40	376.90	315.10	263.20	621.50	600.30	571.70	235.60	360.80	150
Payable Days	254.60	152	192	126.80	212.50	110.50	228.80	164.50	152.60	1,328

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Vysali Pharmaceuticals Ltd FAQs

The current trading price of Vysali Pharma on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Vysali Pharma stood at ₹2.32 Cr

The latest P/E ratio of Vysali Pharma as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Vysali Pharma as of 31-Dec-1969 is -0.26.

The 52-week high of Vysali Pharma is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vysali Pharma is ₹1.17 ( Cr.) .

Data is not available for this company.

No data found

About Vysali Pharmaceuticals Ltd

Vysali Pharmaceuticals Limited incorporated in 1979 is an established Comapny manufacturing Active Pharmaceutical Ingredients of Sterile Injectable Penicillins and its manufacture all formulations from Penicillins to Cephalosporins with dedicated manufacturing facilities for beta lactam range of products. We export our products to various contries in Africa, European Traders, South America and Far East Asian countries. The company is also looking for association with established pharmaceutical Trading companies in various countries for marketing its products

Products off Vysali Pharmaceuticals includes, Sodampen, Crystacin, Gentrobex.

Type of pharmaceuticals

Other Pharmaceuticals (APIs), Penicillins, Polypeptides, Sulfonamides, Quinolones, Tetracyclines, OtherAminoglycosides, Chloramphenicols, Cephalosporins, Glycopeptides, Macrolides.

The registered office address of the company is situated at Seema, 41/427 Rajaji Road,Near Sun International,Ernakulam,Cochin 682035.

Vysali Pharmaceuticals Ltd (524290)

Vysali Pharmaceuticals Ltd (524290)

Vysali Pharmaceuticals stock performance

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Vysali Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Vysali Pharmaceuticals Ltd FAQs

About Vysali Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Vysali Pharmaceuticals Ltd (524290)

Vysali Pharmaceuticals Ltd (524290)

Vysali Pharmaceuticals stock performance

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Vysali Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Vysali Pharmaceuticals Ltd FAQs

What is the share price of Vysali Pharma?

What is the market cap of Vysali Pharma?

What is the P/E ratio of Vysali Pharma?

What is the P/B ratio of Vysali Pharma?

What is the 52-week high and low of Vysali Pharma?

What is the TTM revenue of Vysali Pharma?

Is a good quality company?

Is undervalued or overvalued?

Is a good buy now?

About Vysali Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.